高免疫抑制与风湿病患者COVID-19不良结局相关:ReumaCoV Brasil登记首批结果
ReumaCoV Brasil前瞻性多中心队列前8周纳入334例免疫介导风湿病(IMRD)合并COVID-19患者,分析急诊、住院、ICU、机械通气和死亡的危险因素。多因素调整显示口服糖皮质激素、甲泼尼龙冲击、环磷酰胺及年龄>50岁与不良结局相关,未使用TNFi与住院风险升高相关。
要点
- 口服糖皮质激素和甲泼尼龙冲击与急诊、ICU风险升高相关。
- 甲泼尼龙或环磷酰胺冲击与死亡风险升高相关(PR 2.86)。
- 未使用TNFi与住院风险升高相关,TNFi可能具保护作用。
核心结论
- 年龄>50岁及糖皮质激素、环磷酰胺免疫抑制与COVID-19不良结局相关。
- TNFi治疗可能具有保护作用,或可减轻COVID-19炎症过程。
研究设计与样本
- 观察性多中心前瞻性队列研究(ReumaCoV Brasil登记)前8周分析。
- 纳入符合卫生部标准的IMRD合并COVID-19患者334例,多为女性,中位年龄45岁。
主要发现
- 160例需急诊,33.0%住院,15.0%入ICU,10.5%机械通气,28例(8.4%)死亡。
- 急诊多因素调整:糖尿病PR 1.38(95%CI 1.11–1.73;p=0.004)、肾病PR 1.36(95%CI 1.05–1.77;p=0.020)、口服GC PR 1.49(95%CI 1.21–1.85;p<0.001)、甲泼尼龙冲击PR 1.38(95%CI 1.14–1.67;p=0.001)。
- 住院多因素调整:年龄>50岁PR 1.89(95%CI 1.26–2.85;p=0.002)、未用TNFi PR 2.51(95%CI 1.16–5.45;p=0.004)、甲泼尼龙冲击PR 2.50(95%CI 1.59–3.92;p<0.001)。
- 入ICU多因素调整:口服GC PR 2.24(95%CI 1.36–3.71;p<0.001)、甲泼尼龙冲击PR 1.65(95%CI 1.00–2.68;p<0.043)。
- 死亡相关变量:甲泼尼龙或环磷酰胺冲击PR 2.86(95%CI 1.59–5.14;p<0.018)。
临床怎么用
- 对IMRD合并COVID-19患者,应评估年龄>50岁及糖尿病、肾病等合并症。
- 使用口服GC或甲泼尼龙冲击者需警惕急诊、ICU及住院风险升高。
- 甲泼尼龙或环磷酰胺冲击治疗者死亡风险升高,临床应加强监测。
- 未使用TNFi与住院风险升高相关,TNFi可能具保护作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate risk factors associated with unfavourable outcomes: emergency care, hospitalisation, admission to intensive care unit (ICU), mechanical ventilation and death in patients with immune-mediated rheumatic disease (IMRD) and COVID-19. METHODS: Analysis of the first 8 weeks of observational multicentre prospective cohort study (ReumaCoV Brasil register). Patients with IMRD and COVID-19 according to the Ministry of Health criteria were classified as eligible for the study. RESULTS: 334 participants were enrolled, a majority of them women, with a median age of 45 years; systemic lupus erythematosus (32.9%) was the most frequent IMRD. Emergency care was required in 160 patients, 33.0% were hospitalised, 15.0% were admitted to the ICU and 10.5% underwent mechanical ventilation; 28 patients (8.4%) died. In the multivariate adjustment model for emergency care, diabetes (prevalence ratio, PR 1.38; 95% CI 1.11 to 1.73; p=0.004), kidney disease (PR 1.36; 95% CI 1.05 to 1.77; p=0.020), oral glucocorticoids (GC) (PR 1.49; 95% CI 1.21 to 1.85; p<0.001) and pulse therapy with methylprednisolone (PR 1.38; 95% CI 1.14 to 1.67; p=0.001) remained significant; for hospitalisation, age >50 years (PR 1.89; 95% CI 1.26 to 2.85; p=0.002), no use of tumour necrosis factor inhibitor (TNFi) (PR 2.51;95% CI 1.16 to 5.45; p=0.004) and methylprednisolone pulse therapy (PR 2.50; 95% CI 1.59 to 3.92; p<0.001); for ICU admission, oral GC (PR 2.24; 95% CI 1.36 to 3.71; p<0.001) and pulse therapy with methylprednisolone (PR 1.65; 95% CI 1.00 to 2.68; p<0.043); the two variables associated with death were pulse therapy with methylprednisolone or cyclophosphamide (PR 2.86; 95% CI 1.59 to 5.14; p<0.018). CONCLUSIONS: Age >50 years and immunosuppression with GC and cyclophosphamide were associated with unfavourable outcomes of COVID-19. Treatment with TNFi may have been protective, perhaps leading to the COVID-19 inflammatory process.
引用
- Marques CDL, Kakehasi AM, Pinheiro MM, et al. High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry. RMD Open. 2021. PMID: 33510041. doi:10.1136/rmdopen-2020-001461
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。